| Institute for Research & Innovation |
Multiple Sclerosis - Spasticity
Title: A Randomized, Double-Blind, Placebo-Controlled Efficacy And Safety Of Arbaclofen Placarbil in Subjects with Spasticity due to Multiple SclerosisPurpose: This study is seeking patients who have clinical diagnosed spasticity due to Multiple Sclerosis.
Who Can Participate? Patients who have been diagnosed with spasticity due to Multiple Sclerosis. Patients may be on any or no MS modifying medication.
Diagnosis or Condition: Patients with a clinical diagnosis of Multiple Sclerosis.
Medication: Investigational Product is delivered via oral tablet twice daily.
Age: Between 18 and 70 years
Sex: Males and Females
Visits: Patients will be followed for 15 weeks and complete 8 clinic visits.
Stipend: You will be compensated for your time and travel
Principal Investigator(s): John Huddlestone, MD, FAAN
Study Coordinator: Andrea Thompson, 253-403-7440